# Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)

> **NCT00895882** · PHASE2 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Chronic Genotype 1 Hepatitis C Virus Infection

## Interventions

- **DRUG:** vaniprevir (MK7009)
- **DRUG:** Comparator: vaniprevir (MK7009)
- **DRUG:** Comparator: Pegylated Interferon (peg-IFN) alfa-2a
- **DRUG:** Comparator: Ribavirin
- **DRUG:** Comparator: Placebo to vaniprevir

## Key facts

- **NCT ID:** NCT00895882
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-11
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00895882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00895882, "Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT00895882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*